Publication:
Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

Simple item page
dc.contributor.authorJose Caston, Juan
dc.contributor.authorDe la Torre, Alvaro
dc.contributor.authorRuiz-Camps, Isabel
dc.contributor.authorLuisa Sorli, Maria
dc.contributor.authorTorres, Vicente
dc.contributor.authorTorre-Cisneros, Julian
dc.contributor.authoraffiliation[Jose Caston, Juan] Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed IMIBIC, Clin Unit Infect Dis, Cordoba, Spain
dc.contributor.authoraffiliation[Torre-Cisneros, Julian] Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed IMIBIC, Clin Unit Infect Dis, Cordoba, Spain
dc.contributor.authoraffiliation[Jose Caston, Juan] Inst Salud Carlos III, Spanish Network Res Infect Dis REIPI RD12 2015, Madrid, Spain
dc.contributor.authoraffiliation[Torre-Cisneros, Julian] Inst Salud Carlos III, Spanish Network Res Infect Dis REIPI RD12 2015, Madrid, Spain
dc.contributor.authoraffiliation[De la Torre, Alvaro] Hosp Jaen, Serv Anesthesiol & Reanimat, Jaen, Spain
dc.contributor.authoraffiliation[Ruiz-Camps, Isabel] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain
dc.contributor.authoraffiliation[Luisa Sorli, Maria] Hosp del Mar, Dept Infect Dis, Barcelona, Spain
dc.contributor.authoraffiliation[Torres, Vicente] Hosp Univ Son Espases, Serv Anesthesia & Reanimat, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Torre-Cisneros, Julian] Univ Cordoba, Cordoba, Spain
dc.date.accessioned2023-02-12T02:21:39Z
dc.date.available2023-02-12T02:21:39Z
dc.date.issued2016-12-08
dc.description.abstractInfections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58.3%) was observed.
dc.description.versionSi
dc.identifier.citationCastón JJ, De la Torre Á, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisneros J. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e02136-16
dc.identifier.doi10.1128/AAC.02136-16
dc.identifier.essn1098-6596
dc.identifier.issn0066-4804
dc.identifier.unpaywallURLhttps://europepmc.org/articles/pmc5328537?pdf=render
dc.identifier.urihttp://hdl.handle.net/10668/19011
dc.identifier.wosID394605900006
dc.issue.number3
dc.journal.titleAntimicrobial agents and chemotherapy
dc.journal.titleabbreviationAntimicrob. agents chemother.
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationHospital Universitario de Jaén
dc.page.number4
dc.publisherAmerican Society for Microbiology
dc.relation.publisherversionhttps://journals.asm.org/doi/10.1128/AAC.02136-16?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
dc.rights.accessRightsopen access
dc.subjectPseudomonas aeruginosa
dc.subjectSalvage therapy
dc.subjectCeftolozane-tazobactam
dc.subject.decsInfecciones urinarias
dc.subject.decsTazobactam
dc.subject.meshUrinary-tract-infections
dc.subject.meshDouble-blind
dc.subject.meshCeftolozane/tazobactam
dc.titleSalvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number61
dc.wostypeArticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Reina Sofía
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
SAS - Hospital Universitario de Jaén

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía